1 t child- and young person-centered approach,
we developed 2 robust, age-appropriate versions of an in
2 Here,
we develop 3D printed bionic corals capable of growing m
3 Here,
we develop a "Shotgun" Ion Mobility Mass Spectrometry Se
4 rther pipeline improvement by the community,
we develop a benchmark pipeline for inference of cell-ty
5 Here,
we develop a coarse-grained model to systematically expl
6 Here
we develop a consistent metabolic approach that combines
7 Here,
we develop a dCas9/CRISPR-based system that allows ectop
8 We develop a droplet microfluidic platform to increase t
9 Here,
we develop a facile, general, and high throughput solven
10 Here,
we develop a framework for evaluating and predicting the
11 using a native mouse model of glioblastoma,
we develop a high-throughput in vivo screening platform
12 d the function of these genes in meningioma,
we develop a human cerebral organoid model of meningioma
13 Here
we develop a hypothesis-driven resilience framework for
14 Here
we develop a mathematical model to show, that in highly
15 We develop a mechanistic phenology model and apply it to
16 Here
we develop a method that incorporates both the topology
17 In this work,
we develop a method that separates the faradaic and capa
18 We develop a method to quantify this behavioural variati
19 In this work,
we develop a microfluidic chip formed by HGPS-SMCs gener
20 In this article,
we develop a microfluidic model in which tumor spheroids
21 Based on these observations,
we develop a minimal active-fluid model that reproduces
22 In this study,
we develop a minimal model of Abeta fibrillization to in
23 Given current knowledge of IP(3)Rs,
we develop a model describing the effect of functional i
24 We develop a multi-trait pleiotropy model of the heterog
25 We develop a new tool based on a representation of HiChI
26 We develop a new X-chromosome-based maximum likelihood m
27 Here
we develop a non-invasive method to track spatial oxygen
28 We develop a phenomenological model that nicely reproduc
29 To do so,
we develop a phylogenetic index to quantify the relative
30 In this study,
we develop a pipeline that integrates dimensionality red
31 We develop a pipeline, Antibody Sequence Analysis Pipeli
32 To fill the gap,
we develop a population game model in which migrants are
33 We develop a predictive theoretical model of the physica
34 Here,
we develop a quantitative framework to measure absolute
35 analyses of T cell receptor sequencing data,
we develop a quantitative theory of human T cell dynamic
36 We develop a rigorous nested Jackiw-Rebbi formulation of
37 Here,
we develop a scalable, cost-effective and versatile chem
38 Here,
we develop a sensitive test of trustworthiness evaluatio
39 We develop a series of technologies to test for any nucl
40 Here,
we develop a simple method to test an alternative null h
41 Here,
we develop a simple theoretical framework that allows me
42 Furthermore,
we develop a slow sustained-release strategy to overcome
43 We develop a spatially explicit simulation model that tr
44 Here,
we develop a split dCas12a platform and show that it all
45 We develop a strategy to simulate single-cell transcript
46 for flexural wave focusing and collimation,
we develop a structural wave cloak and waveguide based o
47 We develop a technique, named MNase hypersensitivity seq
48 Here
we develop a theoretical framework that explicitly accou
49 Here,
we develop a transgenic reporter mouse that allows dynam
50 We develop a user-friendly protocol and mobile applicati
51 To fill this critical gap,
we developed a 2D implementation of the Regional Ocean M
52 ther with a commercial scanner manufacturer,
we developed a 4-bed mouse "hotel" to simultaneously ima
53 As a proof of concept,
we developed a 5-plex assay measuring interleukin 5 (IL-
54 ly involved in Ubr1-mediated ubiquitination,
we developed a bead-based assay with covalently immobili
55 We developed a behavioral model to assess this mode of l
56 Here,
we developed a bicistronic biosensor encoding distinct r
57 Here
we developed a bio-hybrid optoelectronic device consisti
58 We developed a bulk superlattice consisting of the trans
59 For this,
we developed a c-di-GMP-sequestering peptide (CSP) that
60 cifically study signal transduction by CARs,
we developed a cell-free, ligand-based activation and ex
61 atform for diagnosis and disease monitoring,
we developed a chemoenzymatic approach that provided an
62 Additionally,
we developed a command line Python tool, mirtop, to crea
63 We developed a compartment model of the United States to
64 We developed a computational framework for identifying p
65 d simultaneously assemble a bipolar spindle,
we developed a computational model of fission-yeast mito
66 We developed a computational pipeline, where the inputs
67 We developed a computational simulation model to quantif
68 We developed a conceptual framework using the metabolic
69 environmental TGFbeta concentration in vivo,
we developed a conditional transgenic mouse model (Flpo/
70 Furthermore, with CLASSED
we developed a context-specific model of beta-adrenergic
71 o cysteines near the eIF4E cap binding site,
we developed a covalent docking approach focused on lysi
72 SS activation in P. aeruginosa Specifically,
we developed a CRISPR interference (CRISPRi) system to k
73 Here,
we developed a CRISPR-based system for simultaneous quan
74 Using these results,
we developed a decision model to estimate probability of
75 We developed a deep-learning system that detects colorec
76 We developed a detailed kinetic model of the fatty acid
77 In this paper,
we developed a facile electrodeposition process for crea
78 opsies including additional features of ATI,
we developed a final multivariate model with a highly si
79 patial resolution of cellular force imaging,
we developed a force-activatable emitter reporting singl
80 To address this challenge,
we developed a framework for integrating tissue-specific
81 To address this deficit,
we developed a fully-automated robotic screening platfor
82 Herein
we developed a general host-guest strategy to fabricate
83 To aid in this effort,
we developed a general population risk calculator for CO
84 Here,
we developed a generic method with a dedicated processin
85 We developed a gradient-based unsupervised clustering me
86 We developed a hepatic organoid platform with human cell
87 We developed a hierarchical Bayesian model to estimate p
88 We developed a high-resolution cryo-EM refinement method
89 Here,
we developed a high-throughput microscopy-based retrotra
90 To leverage this dependency therapeutically,
we developed a highly potent small-molecule inhibitor of
91 To overcome this limitation,
we developed a hybrid data-driven approach based on comb
92 We developed a hybrid ResNet-UNet model CAD system using
93 evaluate the total bioaerosol concentration,
we developed a localized surface plasmon resonance biose
94 Here,
we developed a machine-learning approach to identify sma
95 Here
we developed a macrophage-specific nanotherapy based on
96 To overcome this issue,
we developed a mass spectrometry-based method that quant
97 We developed a mesoscale coarse-grained model to study t
98 We developed a method called GOTI (genome-wide off-targe
99 We developed a method for attaching lipid bilayers to po
100 Thus,
we developed a method that integrates multiple data type
101 Recently,
we developed a method to directly visualize chromatin co
102 Here,
we developed a method to longitudinally monitor the expr
103 In this study,
we developed a method, FamANC, that can improve the accu
104 We developed a miniaturized optoelectronic biosensor usi
105 We developed a minimal mathematical model demonstrating
106 To control expression of transgenes,
we developed a miRNA regulation system that is activated
107 Here,
we developed a mitochondrial 12S ribosomal DNA reference
108 We developed a mobile deep brain recording and stimulati
109 d generation of hydrogen peroxide (H(2)O(2))
we developed a model of intranasal supplementation of po
110 We developed a modeling approach to optimize NG/CT scree
111 We developed a modular nanoparticle system capable of en
112 e role of plasmodesmata in auxin patterning,
we developed a multicellular model of the Arabidopsis ro
113 Here,
we developed a multicolor reporter allele system to gene
114 by CRISPR-Cas9 genome editing in C. elegans
We developed a multiplexed negative selection screening
115 We developed a multiplexing approach using a three-color
116 We developed a natural language processing algorithm to
117 We developed a network model to identify plausible mecha
118 We developed a neurocomputational, bilateral pathway mod
119 To address this challenge,
we developed a new algorithm to identify emerging phenom
120 In this work,
we developed a new approach that address the batch effec
121 We developed a new approach to address this challenge, c
122 olved protease activity profiling in cancer,
we developed a new class of in situ probes that can be a
123 We developed a new framework for individual-based simula
124 Here,
we developed a new method to capture the proteomic micro
125 We developed a new method to detect such candidate genes
126 In this study,
we developed a new methodology, based on digital microfl
127 Here,
we developed a new strategy to incorporate T cells into
128 To address this,
we developed a new toolkit called HemoSYS for quantifyin
129 We developed a new tracer, an (18)F-labeled difluoro-ana
130 By using these data,
we developed a novel approach to characterize cell cycle
131 Here,
we developed a novel c-Myc-targeting compound, N, N-bis
132 Here,
we developed a novel deep learning approach for automate
133 We developed a novel device that increased sorting repro
134 Here,
we developed a novel in vitro assay to characterize the
135 We developed a novel protocol to measure transporter-med
136 To facilitate this,
we developed a novel simulator of single-cell genome evo
137 In this study
we developed a novel technique to estimate B. bacteriovo
138 Here,
we developed a novel Ter119-polymeric NP containing tiss
139 In this study,
we developed a novel ultrasmall Pt(II) dot (uPtD) from m
140 We developed a novel, server-based tool (ICBM-OCEAN, Ins
141 We developed a nucleoside triphosphate (NTP) delivery sy
142 We developed a nucleotide resolution transcriptome-wide,
143 Here,
we developed a one-stop microfluidic platform to assembl
144 We developed a paradigm involving walking in an omnidire
145 From this,
we developed a parameterization for biomass burning BC a
146 affects the number of HIV founder variants,
we developed a phylodynamic model calibrated using genet
147 Here,
we developed a piecewise approach for all-atom steered m
148 To alleviate this issue,
we developed a plug-and-play platform using the spontane
149 We developed a polygenic single nucleotide polymorphism-
150 To address this question,
we developed a polymeric-based constructed graft system
151 We developed a predictive score system for 30-day mortal
152 We developed a preliminary approach to predict 135 adver
153 We developed a prospective cohort of human subjects with
154 We developed a purification strategy enabling assaying o
155 Using these single-cell data,
we developed a quantitative, probabilistic model of cone
156 We developed a rapid and robust separation protocol for
157 In this study,
we developed a rapid and simple capillary electrophoresi
158 Here,
we developed a rat model of incubation of opioid craving
159 underlying these distinct temporal profiles,
we developed a reduced spiking model of sensory cortical
160 Here,
we developed a reporter system to simultaneously monitor
161 Here
we developed a reversal learning task for head-fixed mic
162 Here,
we developed a reversal-learning protocol for the rapid
163 We developed a rhesus macaque model of SARS-CoV-2 infect
164 We developed a risk stratification system from known pro
165 To overcome this,
we developed a series of protease-selective lanthanide-l
166 sing synthetic tap water and new lead pipes,
we developed a set of lead pipes with scales rich in PbO
167 We developed a set of square-shaped, cross-shaped, and c
168 Here,
we developed a simple enzyme-linked immunosorbent assay
169 Here
we developed a simple method based on spontaneous prefer
170 We developed a soybean (Glycine max) assay, BARCSoySNP6K
171 We developed a state-and-transition simulation model tie
172 We developed a statistical AMPA-receptor-tetramer model,
173 To test this hypothesis,
we developed a statistical-thermodynamics-based informat
174 We developed a straightforward U-DNA sequencing method (
175 ing every hydroxyl group by a fluorine atom,
we developed a strategy combining chemical mapping and (
176 To address this formidable challenge,
we developed a supramolecular-synthon-driven approach to
177 ifferences in these residues across species,
we developed a susceptibility score that predicts an ele
178 Based on the spatio-temporal EEG features,
we developed a system for detecting pain perception and
179 We developed a telodendrimer (TD) nanotrap (NT) to captu
180 these cell type-specific immunity networks,
we developed a tool to analyze paired transcription fact
181 To address this gap, here
we developed a transgenic mouse overexpressing Sulf2 in
182 To enable computational design of binders,
we developed a unit of protein structure-a van der Mer (
183 We developed a variant of a GO/NOGO task that reveals im
184 We developed a voluntary, gelatin oral self-administrati
185 We developed a whisker tracker algorithm that automatica
186 We developed acDrug PK assays for next-generation disulf
187 soil properties as predictors of ES proxies,
we developed AESP models: one for spiked and another for
188 We developed algorithms to identify acute AF precipitant
189 In this study,
we develop an agent-based model consisting of the intera
190 Here,
we develop an algorithm (AuxoFind) using genome-scale me
191 Using genetics and mathematical modeling,
we develop an alternative model of scaling driven by fee
192 nt dynamic programming alignment algorithms,
we develop an approximate algorithm based on importance
193 ile minimizing disruption to host processes,
we develop an aqueous-based encapsulation formulation wi
194 Here,
we develop an efficient coding framework for higher-leve
195 Collectively,
we develop an efficient computer program package, gameva
196 We develop an HCC EV purification system (i.e., EV Click
197 We develop an Individualized Network-based Co-Mutation (
198 We develop an omnibus test to assess the informativeness
199 We developed an affordable, highly sensitive, and specif
200 Here,
we developed an anti-AQP3 monoclonal antibody (mAb) that
201 We developed an approach, called 'ZipSeq', that uses pat
202 We developed an automated adaptive atlas algorithm to se
203 To test this hypothesis,
we developed an automated software-based method to perfo
204 Previously,
we developed an efficient method for the simultaneous qu
205 ke structural superfamily as a model system,
we developed an enumerative algorithm for creating a vir
206 s carrying combinations of escape mutations,
we developed an exponential protein barcoding system whi
207 To address this gap in knowledge,
we developed an H-2D(b) LoxP-transgenic mouse system usi
208 Here
we developed an imaging pipeline using plus-end tip trac
209 We developed an indole-carboxamide type mast cell stabil
210 Here,
we developed an inducible system of three-dimensional (3
211 To address this challenge, in this study,
we developed an integrated biorefinery process to upgrad
212 In this work,
we developed an integrative in-cell structural approach
213 Here,
we developed an ON-switch system in which the human reti
214 of targeted motor actions on single trials,
we developed an optical method (COSMOS) for tracking neu
215 Here
we develop and integrate several orthogonal structure-in
216 Here,
we develop and validate a biomathematical framework enco
217 Together,
we developed and characterized a novel fluorescent repor
218 We developed and employed cryo-based methods that preser
219 Here,
we developed and evaluated the rolling circle amplificat
220 To this end,
we developed and implemented a Living Donor Navigator (L
221 We developed and psychometrically validated the AHQ as t
222 Accordingly,
we developed and validated a prognostic index (PIUKALL)
223 rt-hairpin RNAs against PKCdelta or SOM that
we developed and validated.
224 The models
we developed are widely applicable to evaluate the fitne
225 To this end,
we develop AutoRT, a deep learning algorithm with high a
226 We developed average weighted accuracy (AWA), representi
227 To address this
we developed bio-mimetic fish-like robots which allow us
228 Here
we develop bioluminescent circadian reporter mice that a
229 We developed BionoiNet, a new deep learning-based framew
230 To address these needs,
we developed BrainIAK (brainiak.org), an open-source Pyt
231 We developed breakpointR to detect local changes in stra
232 To address this,
we developed CAPTURE (Continuous Appendicular and Postur
233 Here,
we develop CD229 CAR T cells that are highly active in v
234 enables physiological processes to proceed,
we developed CellPhoneDB, a novel repository of ligands,
235 Here
we developed CHOmics, a web-based tool for integrative a
236 For testing M3C,
we developed clusterlab, a new method for simulating mul
237 In this study,
we developed cognitive trajectories for patients with co
238 To attempt to account for our findings,
we developed configural-based computational models invol
239 We developed corto, a fast and lightweight R package to
240 To this end,
we developed covariant ion analysis (COVINA) to investig
241 Finally,
we develop CRISPRview, a technique that integrates immun
242 To address this,
we develop Cyclum, an autoencoder approach identifying c
243 Further,
we develop data normalization methods for accurate predi
244 We developed equations for predicting MAKE30 and MAKE365
245 We developed equations to estimate the median ACR from a
246 We developed FLEXIQuant-LF using label-free quantificati
247 Indeed,
we developed general guidelines for the design of the se
248 We developed gplas, a new approach to reliably separate
249 Using reported measurements,
we developed grass functional trait values (physiologica
250 We develop here an intuitive, powerful and simple-to-imp
251 Here,
we develop hydrogels with identical polymer components b
252 In the present study,
we developed hydrogels from amnion tissue as a delivery
253 To analyze these data,
we developed imagery-encoding models.
254 We developed JUDI on top of DoIt, a Python based WMS, to
255 We developed LeafCutterMD, a new statistical framework t
256 nstructed from the metagenome sequence data,
we developed MapPred, a new deep learning-based contact
257 We developed MASS, a QA method to predict the global qua
258 Here,
we develop mathematical theory to show that the rate of
259 Here
we develop mercury (Hg) stable isotopes as a proxy for p
260 Here,
we developed metagenomic sequencing with spiked primer e
261 In this paper,
we develop methods for correcting statistical inference
262 We develop methods for stable hindbrain calcium imaging
263 data from a theoretical model, in this paper
we develop methods to add signal to real RNA-seq dataset
264 Thus,
we developed mice that lack all of the TRPCs and perform
265 controlled by diverse NUP98-fusion proteins,
we developed mouse models for regulatable expression of
266 yed library of synthetic nanobody sequences,
we developed nanobodies that disrupt the interaction bet
267 We developed neoepiscope chiefly to address this issue f
268 We developed neratinib-resistant HER2-mutant cancer cell
269 Here,
we developed new systems to follow the interactions betw
270 In this work,
we developed NMR chemical shift calculation protocols us
271 Here,
we developed novel nanocarrier delivery of chemotherapy
272 les and genetically engineered mouse models,
we developed organoid systems from primary mouse and hum
273 We developed Pan Resistome Analysis Pipeline (PRAP) for
274 As part of the PCS workflow,
we develop PCS inference procedures, namely PCS perturba
275 Using these structural insights,
we developed PHI1, a BRAF inhibitor that fully uncovers
276 We developed physical models that describe how viscoelas
277 In this paper,
we develop PulseCam - a new camera-based, motion-robust,
278 NA associated with immune-mediated clearance
we developed recombinant strains of SINV that have genom
279 With these challenges in mind,
we developed RIPTiDe (Reaction Inclusion by Parsimony an
280 We developed risk prediction models specific to the mate
281 We developed screening criteria to identify a subset of
282 Here,
we develop selective BET D1 inhibitors with preferred bi
283 We developed serial NEDD8-ubiquitin substrate profiling
284 Accordingly,
we developed spectrally optimized light using programmab
285 Here,
we developed star-shaped particles, termed STAR particle
286 We develop the contamination mixture method, a method fo
287 We develop the theory of the method and demonstrate it o
288 We developed the algorithm STing to provide turn-key sol
289 Thus,
we developed the concept of peptide matrix structure, wh
290 We developed the Continuous-State Hidden Markov Models T
291 Here,
we developed the first biosensor platform for rapid dete
292 We developed the PLate Coverage Algorithm (PLCA) to dete
293 Finally,
we developed the SEARCH-D algorithm for identifying D ge
294 We developed three convolutional neural network (CNN) cl
295 We developed transgenic B. distachyon plants expressing
296 Here,
we develop two human-inspired, discrimination-based beha
297 We develop two models in tandem; an agent-based model th
298 We developed two models under the Bayesian framework: th
299 To facilitate their analysis,
we developed two scores of correlation between sidechain
300 We developed variants with varying binding affinities (K